Information Provided By: 
Fly News Breaks for November 18, 2016
ELGX
Nov 18, 2016 | 08:38 EDT
Stifel analyst Rick Wise says that, after the recent decline in Endologix's stock, investors are getting any U.S. proceeds from its Nelix drug nearly for free. Wise remains confident that the FDA will ultimately approve Nelix, and will generate significant revenues. The analyst thinks that the stock has reached a "compelling entry point," and he keeps a Buy rating on the shares.
News For ELGX From the Last 2 Days
There are no results for your query ELGX
